Is Thermo Fisher Scientific Inc. a good investment?
Thermo Fisher Scientific Inc. (TMO) is currently trading at 673.82 USD.
Market analysts have a consensus price target of 690.62 USD.
This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 37.00.
This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule:
Thermo Fisher Scientific Inc. is expected to release its next earnings report on Feb. 4, 2027.
The market consensus estimate for Forward EPS is 27.58.
For income investors, Thermo Fisher Scientific Inc. pays a dividend yield of 0.27%.
With a payout ratio of 10%, the dividend appears
sustainable.
Company Profile
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Community Discussion